UnitedHealth Group was downgraded from strong buy to buy because its shares appear fully valued at a 20x forward price-to-earnings ratio. The company reported better-than-expected Q3 earnings with revenue of $112.7 billion and earnings per share of $4.69. Management also raised its adjusted EPS guidance for 2026 to at least $20.50. While operational execution, AI-driven efficiencies, and long-term growth targets of 13%-16% support potential upside, valuation concerns and operating risks suggest investors should be cautious and avoid chasing the stock at current levels. The analyst prefers buying below $300 to improve the margin of safety amid sector headwinds and regulatory risks.
UnitedHealth Group trades at USD 398.49 on Pluang as of Oct 19, 2026 18:43 WIB, down 0.73% in the last day. The stock remains well above its 52-week low of USD 259.02 but below its 52-week high of USD 436.35. This pricing context highlights the valuation concerns noted in the analyst downgrade, even as the company shows strong operational performance and raised earnings guidance.
UnitedHealth's stock price fell 51.32% from November 2024 to May 2025, then rose 40.64% by October 2026. These price moves directly influenced its weighting in the SPDR Dow Jones Industrial Average ETF (DIA), which is price-weighted. This means the f...
UnitedHealth's stock has dropped over 10% in three months due to shrinking membership, particularly in Medicare Advantage. Despite this, Morgan Stanley raised its price target to $529, forecasting a 40% upside based on expected margin improvements, g...
